Table 3. Multivariate analysis of relation between clinicopathological factors and platinum-sensitivity status in LS-SCLC.
| Characteristics | OR | 95 CI% | P |
|---|---|---|---|
| ECOG PS (PS 2–3) | 2.221 | 0.681–7.249 | 0.186 |
| Treatment modality (Chemoradiotherapy) | 0.647 | 0.215–1.953 | 0.440 |
| Response (CR + PR) | 0.375 | 0.195–0.722 | 0.003 |
| NSE | |||
| At diagnosis | 1.243 | 1.062–1.484 | 0.011 |
| After four cycles | 2.726 | 2.035–3.684 | < 0.001 |
| At progression | 1.812 | 1.454–2.272 | < 0.001 |
| NLR | |||
| At diagnosis | 1.703 | 1.054–2.757 | 0.013 |
| After four cycles | 2.130 | 1.721–2.656 | 0.002 |
| At progression | 1.743 | 1.056–2.747 | 0.030 |
Abbreviations: LS-SCLC: limited-stage small cell lung cancer; OR: Odds Ratio; CI: confidence interval; ECOG PS: Eastern Cooperative Oncology Group performance status; CR: complete response; PR: partial response; NSE: neuro-specific enolase; NLR: neutrophil-to-lymphocyte.